Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sorafenib, first pharmaceutical drug to improve survival amongst patients with advanced hepatocarcinoma

27.06.2008
International research involving the University Hospital of the University of Navarra, together with other hospitals in Spain, has shown that Sorafenib, an orally administered pharmaceutical medicine, results in patients with primary hepatocarcinomas (liver tumours) to live 40% more on average compared to those not taking the drug.

The study, led by the Barcelona Hospital Clinic, will be shortly published in the New England Journal of Medicine.

This was one of the conclusions of a scientific meeting, organised by the University Hospital of Navarra in Pamplona, which dealt with novelties in the systematic treatment of hepatocarcinoma. Doctor Ruth Vera García, Head of the Oncological Medicine Service at the Hospital of Navarra, Doctor Javier Bustamante Schneider of the Digestive System Service at Cruces Hospital in Bilbao and Doctors Mercedes Iñarrairaegui Bastarrica and Bruno Sangro Gómez-Acebo, both from the Hepatology Unit of the University Hospital of Navarra, presented novelties in the systematic treatment of hepatocarcinoma. The medics coincided in emphasising that the complexity of these patients, often suffering from hepatic cirrhosis also, means that the disorder has to be approached in a multidisciplinary manner and treated at centres which have all possible treatment resources available.

The fifth most common tumour

Hepatocarcinoma is the most frequent hepatic tumour, fifth in overall worldwide cancer rates and the third cause of cancer deaths in the world. In Spain, as in the rest of Mediterranean Europe, some 10 cases per one hundred thousand inhabitants appear every year – a rate of about 500 cases in Spain annually (50 in Navarre). In more than half the cases local curative treatment such as surgery, transplant or percutaneous ablation; or palliative ones, such as arterial embolisation or radioembolisation with radioactive spheres, can be applied.

In the rest of the cases, the prognosis is not good but, in the last five years, there have appeared more than ten pharmaceutical medicines known as biological agents or directed pharmaceutical drugs, the use of which in this tumour is currently being actively investigated, giving rise to a real hope for these patients.

Of these pharmaceutical medicines, Sorafenib has been the first to demonstrate its efficacy and the European Medicines Agency has recently authorised its use for this tumour, given that it can prolong patient survival at the cost of some side effects which, in 80% of cases, are manageable with a number of preventative or therapeutic measures.

Irati Kortabitarte | alfa
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Berri_Kod=1805&hizk=I

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>